Literature DB >> 9520947

Amplification of c-erbB-2 in gastric cancer: detection in formalin-fixed, paraffin-embedded tissue by fluorescence in situ hybridization.

A Ooi1, M Kobayashi, M Mai, I Nakanishi.   

Abstract

A total of 396 adenocarcinomas of the stomach were examined immunohistochemically using antibodies specific for the internal domain of human c-erbB-2 protein. Forty of these (consisting of 35 well-differentiated and 5 undifferentiated types) overexpressed c-erbB-2, as evidenced by cytoplasmic membrane staining; these tumors were further examined by fluorescence in situ hybridization using a cosmid probe for 17q11.2-12 (c-erbB-2 locus) on formalin-fixed, paraffin-embedded tissues. This technique enabled us not only to detect c-erbB-2 amplification on a cell-by-cell basis, but also to compare the gene amplification with the protein expression, observe topographical distribution, and establish quantitative pictures of the amplification in vivo condition. In all 40 tumors, we observed gene amplification and found that the cancer cell with the amplification corresponded to the cells overexpressing c-erbB-2. In eight mucosal carcinomas, signals were coalesced to one or two clusters, indicating that the amplified gene resided in a homogeneous staining region (HSR). Among 32 carcinomas invading beyond muscularis mucosae, approximately half were mostly composed of cells with the amplification; the others had populations of tumor cells with and without amplification, which were sometimes in separate zones or areas and sometimes mixed together. In 22 cancers, the amplified genes were exclusively in HSR; however, cancer cells with multiple scattered signals-suggesting that the amplified genes were translocated to other chromosomes-were found exclusively in 6 tumors and concurrently with HSR in 4 tumors. These findings suggest that: (a) the amplification produces c-erbB-2 in the HSR form generally early in the carcinogenesis of gastric adenocarcinomas; and (b) in the process of cancer development, the amplified gene is lost in some cancer cells by uneven segregation of HSR in mitosis, whereas in others, it is kept in HSR or translocated to other chromosomal positions, thereby preserving overexpression of c-erbB-2 protein.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9520947

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  12 in total

1.  The detection of t(14;18) in archival lymph nodes: development of a fluorescence in situ hybridization (FISH)-based method and evaluation by comparison with polymerase chain reaction.

Authors:  Sharon L Barrans; Paul A S Evans; Sheila J M O'Connor; Roger G Owen; Gareth J Morgan; Andrew S Jack
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

2.  Letter in response to "Our HER2 is same as yours".

Authors:  Satoshi Matsusaka; Kazuhiro Yoshida
Journal:  Transl Gastroenterol Hepatol       Date:  2016-03-16

3.  Extremely well-differentiated adenocarcinoma of the stomach: clinicopathological and immunohistochemical features.

Authors:  Takashi Yao; Takashi Utsunomiya; Masafumi Oya; Kenichi Nishiyama; Masazumi Tsuneyoshi
Journal:  World J Gastroenterol       Date:  2006-04-28       Impact factor: 5.742

4.  HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

Authors:  Pamela L Kunz; Amirkaveh Mojtahed; George A Fisher; James M Ford; Daniel T Chang; Raymond R Balise; Charles D Bangs; Athena M Cherry; Reetesh K Pai
Journal:  Appl Immunohistochem Mol Morphol       Date:  2012-01

5.  HER-2/neu amplification is an independent prognostic factor in gastric cancer.

Authors:  Dong Il Park; Jung Won Yun; Jung Ho Park; Suk Joong Oh; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Chang Hak Yoo; Byung Ho Son; Eun Yoon Cho; Seoung Wan Chae; Eo-Jin Kim; Jin Hee Sohn; Seung Ho Ryu; Antonia R Sepulveda
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

6.  EGFR and HER2 expression in advanced biliary tract cancer.

Authors:  Jan Harder; Oliver Waiz; Florian Otto; Michael Geissler; Manfred Olschewski; Brigitte Weinhold; Hubert E Blum; Annette Schmitt-Graeff; Oliver G Opitz
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

7.  Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinoma.

Authors:  Yao Zheng; Lin Wang; Jian-Ping Zhang; Jing-Yan Yang; Zhu-Mei Zhao; Xiao-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

8.  Targeting HER2 by Combination Therapies.

Authors:  Ana Ruiz-Saenz; Mark M Moasser
Journal:  J Clin Oncol       Date:  2018-01-30       Impact factor: 44.544

9.  Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients.

Authors:  J D Barros-Silva; D Leitão; L Afonso; J Vieira; M Dinis-Ribeiro; M Fragoso; M J Bento; L Santos; P Ferreira; S Rêgo; C Brandão; F Carneiro; C Lopes; F Schmitt; M R Teixeira
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

10.  Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes.

Authors:  Mitsugu Kochi; Masashi Fujii; Shinobu Masuda; Noriaki Kanamori; Yoshiaki Mihara; Tomoya Funada; Hidenori Tamegai; Megumu Watanabe; Hiroshi Suda; Tadatoshi Takayama
Journal:  Diagn Pathol       Date:  2013-11-21       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.